Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
Eyre, T Fox, C Boden, A Bloor, Adrian Dungawalla, M Shankara, P Went, R Schuh, A
Eyre, T
Fox, C
Boden, A
Bloor, Adrian
Dungawalla, M
Shankara, P
Went, R
Schuh, A
Citations
Altmetric:
Abstract
Description
Date
2018-02-22
Publisher
Collections
Keywords
Type
Article
Citation
Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme. 2018, Br J Haematol